F. Javier Ampudia-Blasco

Prof. F. Javier Ampudia-Blasco

orcid
Endocrinology & Nutrition Clinic University Hospital Valenci...

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2019 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
TDThomas Danne
Thomas Danne
SGSatish Garg
Satish Garg
APAnne L. Peters
Anne L. Peters
JBJohn B. Buse
John B. Buse
CMChantal Mathieu
Chantal Mathieu
MPMoshe Phillip
Moshe Phillip
Sodium–glucose cotransporter (SGLT) inhibitors are new oral antidiabetes medications shown to effectively reduce glycated hemoglobin (A1C) and glycemic variability, blood pressure, and body weight without intrinsic properties to cause hypoglycemia in people with type 1 diabetes. However, recent studies, particularly in individuals with type 1 diabetes, have demonstrated increases in the absolute risk of diabetic ketoacidosis (DKA). Some cases presented with near-normal blood glucose levels or mild hyperglycemia, complicating the recognition/diagnosis of DKA and potentially delaying treatment. Several SGLT inhibitors are currently under review by the U.S. Food and Drug Administration and European regulatory agencies as adjuncts to insulin therapy in people with type 1 diabetes. Strategies must be developed and disseminated to the medical community to mitigate the associated DKA risk. This Consensus Report reviews current data regarding SGLT inhibitor use and provides recommendations to enhance the safety of SGLT inhibitors in people with type 1 diabetes.

6 October 2009 in Diabetes Care
Verified
Journal Article
Open access
PDF file
MRMaria C.E. Rossi
Maria C.E. Rossi
ANAntonio Nicolucci
Antonio Nicolucci
PBPaolo Di Bartolo
Paolo Di Bartolo
DBDaniela Bruttomesso
Daniela Bruttomesso
AGAngela Girelli
Angela Girelli
GVGiacomo Vespasiani
Giacomo Vespasiani
OBJECTIVE Widespread use of carbohydrate counting is limited by its complex education. In this study we compared a Diabetes Interactive Diary (DID) with standard carbohydrate counting in terms of metabolic and weight control, time required for education, quality of life, and treatment satisfaction. RESEARCH DESIGN AND METHODS Adults with type 1 diabetes were randomly assigned to DID (group A, n = 67) or standard education (group B, n = 63) and followed for 6 months. A subgroup also completed the SF-36 Health Survey (SF-36) and World Health Organization-Diabetes Treatment Satisfaction Questionnaire (WHO-DTSQ) at each visit. RESULTS Of 130 patients (aged 35.7 ± 9.4 years; diabetes duration 16.5 ± 10.5 years), 11 dropped out. Time for education was 6 h (range 2–15 h) in group A and 12 h (2.5–25 h) in group B (P = 0.07). A1C reduction was similar in both groups (group A from 8.2 ± 0.8 to 7.8 ± 0.8% and group B from 8.4 ± 0.7 to 7.9 ± 1.1%; P = 0.68). Nonsignificant differences in favor of group A were documented for fasting blood glucose and body weight. No severe hypoglycemic episode occurred. WHO-DTSQ scores increased significantly more in group A (from 26.7 ± 4.4 to 30.3 ± 4.5) than in group B (from 27.5 ± 4.8 to 28.6 ± 5.1) (P = 0.04). Role Physical, General Health, Vitality, and Role Emotional SF-36 scores improved significantly more in group A than in group B. CONCLUSIONS DID is at least as effective as traditional carbohydrate counting education, allowing dietary freedom for a larger proportion of type 1 diabetic patients. DID is safe, requires less time for education, and is associated with lower weight gain. DID significantly improved treatment satisfaction and several quality-of-life dimensions.

29 July 2005 in Diabetologia
Verified
Journal Article
Closed access
PDF file
WRW. Ricart
W. Ricart
JLJ. López
J. López
JMJ. Mozas
J. Mozas
APA. Pericot
A. Pericot
MSM. A. Sancho
M. A. Sancho
FTFor the Spanish Group for the Study of the Impact of Carpenter and Coustan GDM Thresholds
For the Spanish Group for the Study of the Impact of Carpenter and Coustan GDM Thresholds

12 May 2005 in Diabetologia
Verified
Journal Article
Closed access
PDF file
WRW. Ricart
W. Ricart
JLJ. López
J. López
JMJ. Mozas
J. Mozas
APA. Pericot
A. Pericot
MSM. A. Sancho
M. A. Sancho
STSpanish Group for the Study of the Impact of Carpenter and Coustan GDM thresholds
Spanish Group for the Study of the Impact of Carpenter and Coustan GDM thresholds

14 March 2024 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
ASAlba Galdón Sanz-Pastor
Alba Galdón Sanz-Pastor
AEAlicia Justel Enríquez
Alicia Justel Enríquez
ABAna Sánchez Bao
Ana Sánchez Bao
F. Javier Ampudia-BlascoF. Javier Ampudia-Blasco
F. Javier Ampudia-Blasco
Insulin is an essential drug in the treatment of diabetes, often necessary for managing hyperglycemia in type 2 diabetes mellitus (T2DM). It should be considered in cases of severe hyperglycemia requiring hospitalization, after the failure of other treatments, in advanced chronic kidney disease, liver cirrhosis, post-transplant diabetes, or during pregnancy. Moreover, in specific patient subgroups, early initiation of insulin is crucial for hyperglycemia control and prevention of chronic complications. Clinical guidelines recommend initiating insulin when other treatments fail, although there are barriers that may delay its initiation. The timing of initiation depends on individual patient characteristics. Typically, insulinization starts by adding basal insulin to the patient’s existing treatment and, if necessary, progresses by gradually introducing prandial insulin. Several barriers have been identified that hinder the initiation of insulin, including fear of hypoglycemia, lack of adherence, the need for glucose monitoring, the injection method of insulin administration, social rejection associated with the stigma of injections, weight gain, a sense of therapeutic failure at initiation, lack of experience among some healthcare professionals, and the delayed and reactive positioning of insulin in recent clinical guidelines. These barriers contribute, among other factors, to therapeutic inertia in initiating and intensifying insulin treatment and to patients’ non-adherence. In this context, the development of once-weekly insulin formulations could improve initial acceptance, adherence, treatment satisfaction, and consequently, the quality of life for patients. Currently, two once-weekly basal insulins, insulin icodec and basal insulin BIF, which are in different stages of clinical development, may help. Their longer half-life translates to lower variability and reduced risk of hypoglycemia. This review addresses the need for insulin in T2DM, its positioning in clinical guidelines under specific circumstances, the current barriers to initiating and intensifying insulin treatment, and the potential role of once-weekly insulin formulations as a potential solution to facilitate timely initiation of insulinization, which would reduce therapeutic inertia and achieve better early control in people with T2DM.

25 July 2017 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
CMCintia Muñoz-Quiles
Cintia Muñoz-Quiles
MLMónica López-Lacort
Mónica López-Lacort
F. Javier Ampudia-BlascoF. Javier Ampudia-Blasco
F. Javier Ampudia-Blasco
JDJAVIER DIEZ DOMINGO
JAVIER DIEZ DOMINGO
Aims: This study was designed to assess the impact of diabetes on the risk and severity of herpes zoster (HZ), and the impact of HZ on diabetes. It focused primarily on immunocompetent patients aged ≥ 50 years who would be eligible for preventive vaccination. Methods: Using population and healthcare databases of Valencia Region (Spain), a retrospective cohort of all subjects ≥ 50 years was followed up between 2009 and 2014. HZ and diabetes were defined using ICD-9 codes. We compared the incidence of HZ between non-diabetes and diabetes groups and healthcare resource consumption due to HZ in the 6 months following HZ diagnosis using different statistical generalized linear models (GLM). We also compared resources consumption due to diabetes treatment and haemoglobinA1c(HbA1c) levels before and after HZ. Results: The cohort consisted of 2,289,485 individuals ≥ 50 years old, 397,940 of whom had diabetes. HZ incidence rate was 9.3 cases/1000 persons with diabetes-year (95% CI: 9.1–9.4). Incidence increased with age in all groups. The risk of HZ increased in the diabetes group compared to the non-diabetes group (RR 1.2, 95% credibility interval [CrI] 1.17–1.22). Patients with diabetes utilized more health care resources due to their HZ episodes than patients without diabetes. In 24% of well controlled patients with diabetes (HbA1C levels ≤ 6.5%), HbA1C increased after HZ. Conclusions: Diabetes increased by 20% the risk of HZ. HZ contributed to the deterioration of glycaemic control and higher healthcare resource consumption in people with diabetes, becoming a priority population for HZ immunization.